Stroll Secures £10.3m Funding Boost for Neurological Disorder Therapy
Deal News | Mar 13, 2025 | Martlet Capital
Strolll, a company specializing in Digital Therapeutics software for Augmented Reality glasses, has successfully secured £10.3 million in funding. This development was primarily led by IW Capital, with Martlet Capital, a prior investor, maintaining an active role. Founded five years ago, Strolll dedicates itself to developing therapies for those suffering from neurological disorders such as Parkinson's and multiple sclerosis. Recently, the company launched a three-year trial project funded by the National Institute for Health and Care Research in collaboration with prominent UK universities and NHS trusts, to examine the therapeutic potential of Strolll for Parkinson's patients. Additionally, Strolll has expanded into the US market with the support of the Cleveland Clinic. The funding will be used to boost sales and marketing efforts, broaden their product offerings, and explore additional neurological disorders.
Sectors
- Healthcare Technology
- Augmented Reality
- Investment
Geography
- United Kingdom – Strolll is headquartered in the UK, undertaking trial projects with UK universities and NHS trusts.
- United States – Strolll's expansion into the US market, supported by the Cleveland Clinic, connects the article to this geography.
Industry
- Healthcare Technology – Strolll develops Digital Therapeutics software, a significant segment of the healthcare technology industry, focusing on treatment for neurological disorders.
- Augmented Reality – The use of Augmented Reality glasses by Strolll highlights its integration with advanced technologies to enhance therapeutic approaches.
- Investment – The article discusses a funding round led by investors, marking the relevance of the investment industry.
Financials
- £10.3 million – Total amount of funding secured by Strolll in the latest round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Strolll | Target Company | Company | A developer of Digital Therapeutics software aimed at aiding those with neurological disorders. |
| IW Capital | Bidding Company | Company | Led the latest funding round for Strolll. |
| Martlet Capital | PE Investor | Company | A private equity investor that had initially invested in Strolll during its seed round. |
| National Institute for Health and Care Research | Grant Provider | Government | Provided funding for a trial project involving Strolll. |
| University of Leeds | Research Partner | Company | Participating in the trial project with Strolll. |
| University of York | Research Partner | Company | Participating in the trial project with Strolll. |
| Cleveland Clinic | Shareholder | Company | Supporting Strolll's entry into the US market. |
| NHS Trusts | Research Partner | Government | Collaborating in the clinical trial of Strolll's therapy. |